Table 1 Baseline characteristics and comorbidities

N

78,086

530

Age at index date, mean (SD) [years]

69.9 (13.4)

77.4 (9.1)

Age groups, [n, %]

   < 45

4122 (5.3%)

1 (0.2%)

   45–64

19,061 (24.4%)

52 (9.8%)

   65–74

19,028 (24.4%)

98 (18.5%)

   75–84

28,324 (36.3%)

256 (48.3%)

   ≥ 85

7551 (9.7%)

123 (23.2%)

Gender, [n, %]

   Male

45,256 (58.0%)

309 (58.3%)

   Female

32,830 (42.0%)

221 (41.7%)

DOAC indications, [n, %]

   Venous thromboembolism

26,656 (34.1%)

122 (23.0%)

   Atrial fibrillation

56,826 (72.8%)

457 (86.2%)

   Non-mechanical cardiac-valve replacement

2242 (2.9%)

20 (3.8%)

Comorbidities, [n, %]

   Updated Charlson Comorbidity Index

(mean, [SD])

2.4 (2.2)

3.7 (2.4)

   Diabetes type 1

2324 (3.0%)

20 (3.8%)

   Diabetes type 2

23,334 (29.9%)

215 (40.6%)

   Chronic kidney disease

18,422 (23.6%)

208 (39.3%)

   Hypercholesterolemia

21,762 (27.9%)

175 (33.0%)

   Hypertension

62,449 (80.0%)

486 (91.7%)

   Coronary artery disease

26,082 (33.4%)

244 (46.0%)

   Stroke

10,428 (13.4%)

151 (28.5%)

   - Ischemic stroke

8545 (10.9%)

123 (23.2%)

   - Haemorrhagic stroke

734 (0.9%)

29 (5.5%)

   - Transitory ischemic attack

3180 (4.1%)

44 (8.3%)

   Heart failure

26,444 (33.9%)

263 (49.6%)

Major bleeding history > 60 days prior to FXai start

3671 (4.7%)

50 (9.43%)

   Gastrointestinal diseases

43,898 (56.2%)

334 (63.0%)

   Anaemia

8788 (11.3%)

93 (17.6%)

   Urological diseases

27,866 (35.7%)

245 (46.2%)

Comedications, [n, %]

   History of non-FXai AC use

7339 (9.4%)

29 (5.5%)

   Lipid lowering therapies

26,681 (34.2%)

266 (50.2%)

   Anticancer therapies

1554 (2.0%)

17 (3.2%)

   NSAIDs

26,836 (34.4%)

154 (29.1%)

   Antiplatelet drugs

14,273 (18.3%)

95 (17.9%)

   Antidepressants

10,341 (13.2%)

110 (20.8%)

   Antivirals

1251 (1.6%)

11 (2.1%)

   Corticosteroids

10,533 (13.5%)

53 (10.0%)

   Gastroprotective agents

28,354 (36.3%)

252 (47.6%)

   Hormone therapies

1290 (1.7%)

12 (2.3%)

   Macrolides

4266 (5.5%)

20 (3.8%)